PCT

PureCycle remains a development-stage story dressed as a $1.4B company. FY2025 revenue was just $8.36M against a $183M net loss, putting the stock at an absurd 164.7x price-to-sales. The company is not yet a real operating business: management's own 10-K devotes its MDA to a Going Concern assessment under ASC 205-40 and flags 'our ability to obtain funding for our operations... and to continue as a going concern' as the first risk factor, alongside whether the flagship Ironton facility can even 'be appropriately certified by Leidos... and commence full-scale commercial operations in a timely and cost-effective manner, or at all.' That is the language of a company whose core asset is still unproven at scale.

The balance sheet underscores the fragility. Stockholders' equity collapsed 74.6% to $45.9M while the accumulated deficit deepened to -$816M, leaving liabilities at 12.47x equity — a hair from negative book value. The $157M cash pile (up sharply on financing, not operations) is the only cushion, and it is thin: operating cash burn ran -$143M in FY2025 plus $40.8M of capex, implying barely a year of runway before the company must raise again. With 181M shares and a depressed price, any raise is likely dilutive equity or more debt onto an already-strained structure.